Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses

PRIMARY OBJECTIVES:

I. To examine and compare the distribution of CEUS parameters in breast masses that were evaluated as Breast Imaging Reporting and Data System (BI-RADS) 4a, 4b, 4c or 5 by conventional ultrasound (US) and were recommended for ultrasound guided biopsy, and to evaluate whether these parameters can be used to classify suspicious cystic-appearing breast masses as benign or malignant.

Ia. To develop a CEUS-based radiomics workflow to extract radiomic metrics (> 1600 features) in classifying breast mass malignancy (Radiomics).

Ib. To develop a systematic and rigorous machine learning (ML)-based framework comprised of classification, cross-validation and statistical analyses to identify classifiers for breast malignancy stratification based on CEUS-derived radiomic metrics (time-intensity curve [TIC] analysis and Radiomics) and deep learning approaches.

Ic. To assess the independent contribution of radiomics classifier, time-intensity curve and deep learning classifier to the model accuracy in discriminating benign from malignant cases using CEUS.

Id. To develop a contrast-enhanced spectral mammography (CESM)-based radiomics workflow to extract radiomic metrics (> 1600 features) in classifying breast mass malignancy (Radiomics).

Ie. To develop a systematic and rigorous machine learning (ML)-based framework comprised of classification, cross-validation and statistical analyses to identify classifiers for breast malignancy stratification based on CESM-derived radiomic metrics (TIC analysis and Radiomics) and deep learning approaches.

If. To assess the independent contribution of radiomics classifier, time-intensity curve and deep learning classifier to the model accuracy in discriminating benign from malignant cases using CESM.

Ig. To assess the potential benefit of an ensemble framework to integrate the different artificial intelligence (Al) classifiers (TIC analysis, Radiomics and Deep learning) in preventing unnecessary biopsy.

OUTLINE:

Patients receive a contrast agent (Lumason or DEFINITY) intravenously (IV) and then undergo CEUS scan over 60-90 minutes and/or receive iohexol IV and undergo CESM on study.